Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Publication charge
Books and Events
Books
Events
ORIGINAL PAPER
The kynurenine pathway in patients with rheumatoid arthritis during tumor necrosis factor α inhibitors treatment
1
Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan University of Medical Sciences, Poland
Submission date: 2024-07-04
Final revision date: 2024-07-27
Acceptance date: 2024-07-29
Online publication date: 2024-08-27
Corresponding author
Dorota Sikorska
Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan University of Medical Sciences, 135/147 28 Czerwca 1956 r. St., 61-545 Poznan, Poland
Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan University of Medical Sciences, 135/147 28 Czerwca 1956 r. St., 61-545 Poznan, Poland
Reumatologia 2024;62(4):220-225
KEYWORDS
TOPICS
ABSTRACT
Objectives:
The importance of the kynurenine pathway in normal immune system function has led to an appreciation of its possible contribution to autoimmune disorders such as rheumatoid arthritis (RA). The aim of the study was to evaluate the effect of treatment with tumor necrosis factor α (TNF-α) inhibitors on the activity of the kynurenine pathway in patients with RA.
Material and methods:
This was an investigator-initiated, prospective, observational study. The study was performed on 30 RA patients (Caucasian, 11 male, 19 female; mean age 45 ±16 years) treated with TNF-α inhibitors. All patients were assessed before and after 6 months of therapy. As a control group, age- and sex-matched, 20 healthy volunteers were recruited. Disease activity was evaluated by the Modified Disease Activity Score with 28-joint count (DAS28). Inflammatory markers were assessed routinely by the hospital central laboratory. Serum concentrations of kynurenine, serotonin and tryptophan were measured with specific immunoassays. To estimate indoleamine 2,3-dioxygenase (IDO) activity, kynurenine-to-tryptophan ratio was calculated.
Results:
The results of our study showed changes in tryptophan metabolism in RA patients, compared with healthy controls. Surprisingly, RA patients had statistically significant decreased kynurenine-to-tryptophan ratio (p = 0.003), which could indicate diminished IDO activation in RA. Moreover, we found no significant changes in kynurenine-to-tryptophan ratio after treated with TNF-α inhibitors (p = 0.490), despite disease remission. Additionally, tryptophan metabolism activity did not correlate with objective markers of inflammation.
Conclusions:
The RA patients had altered tryptophan metabolism, compared with healthy controls. The mechanisms affecting tryptophan metabolism in RA may be complex. We believe that continuing elucidation of pathophysiological pathways relevant in RA offer substantial hope for the development of specific pharmacotherapy for treatment of RA – especially for comorbidity of RA and depression.
The importance of the kynurenine pathway in normal immune system function has led to an appreciation of its possible contribution to autoimmune disorders such as rheumatoid arthritis (RA). The aim of the study was to evaluate the effect of treatment with tumor necrosis factor α (TNF-α) inhibitors on the activity of the kynurenine pathway in patients with RA.
Material and methods:
This was an investigator-initiated, prospective, observational study. The study was performed on 30 RA patients (Caucasian, 11 male, 19 female; mean age 45 ±16 years) treated with TNF-α inhibitors. All patients were assessed before and after 6 months of therapy. As a control group, age- and sex-matched, 20 healthy volunteers were recruited. Disease activity was evaluated by the Modified Disease Activity Score with 28-joint count (DAS28). Inflammatory markers were assessed routinely by the hospital central laboratory. Serum concentrations of kynurenine, serotonin and tryptophan were measured with specific immunoassays. To estimate indoleamine 2,3-dioxygenase (IDO) activity, kynurenine-to-tryptophan ratio was calculated.
Results:
The results of our study showed changes in tryptophan metabolism in RA patients, compared with healthy controls. Surprisingly, RA patients had statistically significant decreased kynurenine-to-tryptophan ratio (p = 0.003), which could indicate diminished IDO activation in RA. Moreover, we found no significant changes in kynurenine-to-tryptophan ratio after treated with TNF-α inhibitors (p = 0.490), despite disease remission. Additionally, tryptophan metabolism activity did not correlate with objective markers of inflammation.
Conclusions:
The RA patients had altered tryptophan metabolism, compared with healthy controls. The mechanisms affecting tryptophan metabolism in RA may be complex. We believe that continuing elucidation of pathophysiological pathways relevant in RA offer substantial hope for the development of specific pharmacotherapy for treatment of RA – especially for comorbidity of RA and depression.
REFERENCES (37)
1.
Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet (London, England) 2001; 358: 903–911, DOI: 10.1016/S0140-6736(01)06075-5.
2.
Karmakar U, Vermeren S. Crosstalk between B cells and neutrophils in rheumatoid arthritis. Immunology 2021; 164: 689–700, DOI: 10.1111/imm.13412.
3.
Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci 2021; 22: 10922, DOI: 10.3390/ijms222010922.
4.
Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration. Ann Rheum Dis 2022; 81: 1358–1366, DOI: 10.1136/annrheumdis-2022-222586.
5.
Kato M. New insights into IFN- in rheumatoid arthritis: role in the era of JAK inhibitors. Immunol Med 2020; 43: 72–78, DOI: 10.1080/25785826.2020.1751908.
6.
Lee K, Min HK, Koh SH, et al. Prognostic signature of interferon- and interleurkin-17A in early rheumatoid arthritis. Clin Exp Rheumatol 2022; 40: 999–1005, DOI: 10.55563/clinexprheumatol/mkbvch.
7.
Huang YS, Ogbechi J, Clanchy FI, et al. IDO and kynurenine metabolites in peripheral and CNS disorders. Front Immunol 2020; 11: 388, DOI: 10.3389/fimmu.2020.00388.
8.
Buras A, Waszkiewicz N, Szulc A. Depresja i proces zapalny w chorobach reumatologicznych [Depression and inflammation in rheumatic diseases]. Postepy Hig Med Dosw (Online) 2016; 70: 162-168, DOI: 10.5604/17322693.1196386 [Article in Polish].
9.
Ogbechi J, Clanchy FI, Huang YS, et al. IDO activation, inflammation and musculoskeletal disease. Exp Gerontol 2020; 131: 110820, DOI: 10.1016/j.exger.2019.110820.
10.
Ren H, Lin F, Wu L, et al. The prevalence and the effect of interferon- in the comorbidity of rheumatoid arthritis and depression. Behav Brain Res 2023; 439: 114237, DOI: 10.1016/j.bbr.2022.114237.
11.
Forrest CM, Kennedy A, Stone TW, et al. Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. Adv Exp Med Biol 2003; 527: 287–295, DOI: 10.1007/978-1-4615-0135-0_32.
12.
Schroecksnadel K, Winkler C, Duftner C, et al. Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 2006; 25: 334–337, DOI: 10.1007/s10067-005-0056-6.
13.
Pongratz G, Lowin T, Sewerin P, et al. Tryptophan metabolism in rheumatoid arthritis is associated with rheumatoid factor and predicts joint pathology evaluated by the Rheumatoid Arthritis MRI Score (RAMRIS). Clin Exp Rheumatol 2019; 37: 450–457.
14.
Schroecksnadel K, Kaser S, Ledochowski M, et al. Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J Rheumatol 2003; 30: 1935–1939.
15.
Kolodziej L. Systemic metabolism of tryptophan and its catabolites, kynurenine and 3-HAA, in mice with inflammatory arthritis. Gene 2013; 512: 23–27, DOI: 10.1016/j.gene.2012.09.122.
16.
Kolodziej L. Investigation of the kynurenine pathway in indoleamine 2, 3 dioxygenase deficient mice with inflammatory arthritis. Transgenic Res 2013; 22: 1049–1054, DOI: 10.1007/s11248-013-9696-5.
17.
Spiera H, Vallarino R. Serum kynurenine in rheumatoid arthritis. J Clin Invest 1969; 48: 856–859, DOI: 10.1172/JCI106043.
18.
Parada-Turska J, Zgrajka W, Majdan M. Kynurenic acid in synovial fluid and serum of patients with rheumatoid arthritis, spondyloarthropathy, and osteoarthritis. J Rheumatol 2013; 40: 903–909, DOI: 10.3899/jrheum.121035.
19.
Ozkan Y, Mete G, Sepici-Dincel A, et al. Tryptophan degradation and neopterin levels in treated rheumatoid arthritis patients. Clin Rheumatol 2012; 31: 29–34, DOI: 10.1007/s10067-011-1767-5.
20.
Kurz K, Herold M, Winkler C, et al. Effects of adalimumab therapy on disease activity and interferon--mediated biochemical pathways in patients with rheumatoid arthritis. Autoimmunity 2011; 44: 235–242, DOI: 10.3109/08916934.2010.528476.
21.
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–2581, DOI: 10.1002/art.27584.
22.
Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79: 685–699, DOI: 10.1136/annrheumdis-2019-216655.
23.
Prevoo ML, van‘t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–48, DOI: 10.1002/art.1780380107.
24.
van Gestel AM, Prevoo ML, van‘t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34–40, DOI: 10.1002/art.1780390105.
25.
Ye Z, Yue L, Shi J, et al. Role of IDO and TDO in cancers and related diseases and the therapeutic implications. J Cancer 2019; 10: 2771–2782, DOI: 10.7150/jca.31727.
26.
Yurt EF, Biçer C, Serdar MA, et al. Accelerated kynurenine pathway downregulates immune activation in patients with axial spondyloarthritis. Cytokine 2023; 169: 156247, DOI: 10.1016/j.cyto.2023.156247.
27.
Åkesson K, Pettersson S, Ståhl S, et al. Kynurenine pathway is altered in patients with SLE and associated with severe fatigue. Lupus Sci Med 2018; 5: e000254, DOI: 10.1136/lupus-2017-000254.
28.
Labadarios D, McKenzie DY, Dickerson JW, Parke DV. Metabolic abnormalities of tryptophan and nicotinic acid in patients with rheumatoid arthritis. Rheumatol Rehabil 1978; 17: 227–232, DOI: 10.1093/rheumatology/17.4.227.
29.
Bett IM. Urinary tryptophan metabolites in rheumatoid arthritis and some other diseases. Ann Rheum Dis 1966; 25: 556–562, DOI: 10.1136/ard.25.6.556.
30.
Panfili E, Gerli R, Grohmann U, Pallotta MT. Amino acid metabolism in rheumatoid arthritis: friend or foe? Biomolecules 2020; 10: 1280, DOI: 10.3390/biom10091280.
31.
Weyh C, Krüger K, Strasser B. Physical activity and diet shape the immune system during aging. Nutrients 2020; 12: 622, DOI: 10.3390/nu12030622.
32.
Evrensel A, Ünsalver B, Ceylan ME. Immune-kynurenine pathways and the gut microbiota-brain axis in anxiety disorders. Adv Exp Med Biol 2020; 1191: 155–167, DOI: 10.1007/978-981-32-9705-0_10.
33.
Müller N. Immunology of major depression. Neuroimmunomodulation 2014; 21: 123–130, DOI: 10.1159/000356540.
34.
Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005; 25: 20–30, DOI: 10.1089/jir.2005.25.20.
35.
Werner-Felmayer G, Werner ER, Fuchs D, et al. Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler 1989; 370: 1063–1069, DOI: 10.1515/bchm3.1989.370.2.1063.
36.
Schuerwegh AJ, Van Offel JF, Stevens WJ, et al. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford) 2003; 42: 541–548, DOI: 10.1093/rheumatology/keg171.
37.
Müller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 2010; 11: 31–42.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
